At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,099 enrolled
Drug / intervention
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
In Brief
An observational study evaluating bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 1,099 participants across 1 site.
Detailed Summary
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
Primary CompletionSep 2007
First PostedJul 2008
Study CompletionSep 2009
TodayJul 2026
First PostedJul 16, 2008
Enrollment StartSep 1, 2004
Primary CompletionSep 1, 2007
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.0 years ago
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%drug
1 drop in eye(s) every evening